BioLine RX Stock

BioLine RX Net Margin

Delisted

The Net Profit Margin of BioLine RX (BLRX.TA) as of Jul 16, 2026 is -31.86 %. In the previous year, Net Profit Margin was -1,262.79 % — a change of -97.48% (higher).

Net Margin

-31.86 %

YoY

-97.48%

Last updated:

Net Profit Margin of BioLine RX is 2026 -31.86 % . Net Profit Margin of BioLine RX was 2025 -1,262.79 % . It decreases by -97.48% higher compared to the previous year.

BioLine RX's net margin stands at -31.9%, up from -96.3% several years earlier.

Access this data via the Eulerpool API

BioLine RX Stock analysis

What does BioLine RX do? BioLine RX Ltd is a global biopharmaceutical company specializing in the development of novel therapies for cancer and other serious diseases. The company is headquartered in Israel and has offices in the United States and Europe. BioLine RX is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioLine RX stock

Net Profit Margin of BioLine RX is -31.86 % in 2026.

Access this data via the Eulerpool API

Margins — BioLine RX

All Key Metrics — BioLine RX